# Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

> **NCT03222089** · PHASE2 · WITHDRAWN · sponsor: **Fujian Cancer Hospital**

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Oxaliplatin
- **DRUG:** Levoleucovorin
- **DRUG:** 5-FU
- **DRUG:** GM-CSF
- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT03222089
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-07-20
- **Primary completion:** 2019-07-20
- **Final completion:** 2020-07-20
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Another study enrolling the similar group of patient are ongoing
- **Last updated:** 2018-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03222089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03222089, "Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03222089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*